|
|
| Line 124: |
Line 124: |
| |- | | |- |
| !Drug | | !Drug |
| !Drugs that ↑ drug action | | !Drugs that <big>↑</big> drug action |
| !Drugs that ↓ drug action | | !Drugs that <big>↓</big> drug action |
| |- | | |- |
| !Digoxin | | !Digoxin |
| Line 506: |
Line 506: |
| |Hyperlipidaemias of types IIa, IIb, III, IV and V | | |Hyperlipidaemias of types IIa, IIb, III, IV and V |
| |Gemfibrozil: 0.9-1.2mg daily | | |Gemfibrozil: 0.9-1.2mg daily |
| |Gastro-intestinal disturbances including dyspepsia (19.6%), nausea (4%), abdominal pain (9.8%), diarrhoea (7.2%), vomiting (1.2%); headache (1.2%), fatigue (3.8%), vertigo (1.5%), eczema, rash (1.7%), atrial fibrillation (0.7%), pancreatitis, appendicitis, disturbances in liver function including hepatitis and cholestatic jaundice, dizziness, paraesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia, eosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia, myositis accompanied by increase in creatine kinase, blurred vision, exfoliative dermatitis, alopecia, and photosensitivity<cite>Esc43</cite> | | |Gastro-intestinal |
| |-
| |
| |Ezetimibe
| |
| |Primary and familial hyper-cholesterolaemia
| |
| |10mg once daily
| |
| |Gastro-intestinal disturbance including diarrhoea (4.1%) and abdominal pain (3.0%); headache, fatigue (2.4%); myalgia, arthralgia (3.0%), sinusitis (3.6%), pharyngitis (2.3%), viral infection (2.2%), coughing (2.3%), hypersensitivity reactions including rash, angioedema, and anaphylaxis, hepatitis,pancreatitis, cholelithiasis, cholecystitis, thrombocytopenia, raised creatine kinase, myopathy, and rhabdomyolysis<cite>Esc44</cite>
| |
| |}
| |
|
| |
|
| ==References== | | ==References== |